Inventor · disambiguated record
Troy Douglas Smith
Also filed as: SMITH TROY · SMITH TROY D · SMITH TROY DOUGLAS
15 granted patents·11 pending applications·147 citations·filing 2006–2024
92Inventor score
Files withNOVARTIS AG19BESONG GILBERT2BESONG GILBERT EBAI1CAFERRO THOMAS RAYMOND1CHEN CHRISTINE HIU-TUNG1
Top patents by PatentIndex Score
26 records- 0194US8685980B2Pyrrolopyrimidine compounds and their usesBESONG GILBERT EBAI·Filed 2009·Granted Apr 1, 2014·81 cites·15 claims
- 0292US10968235B2N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2NOVARTIS AG·Filed 2019·Granted Apr 6, 2021·3 cites·3 claims
- 0392US10934285B2Compounds and compositions for inhibiting the activity of SHP2NOVARTIS AG·Filed 2017·Granted Mar 2, 2021·5 cites·5 claims
- 0492US10077276B2N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2CHEN CHRISTINE HIU TUNG·Filed 2015·Granted Sep 18, 2018·15 cites·22 claims
- 0590US10336774B2N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2NOVARTIS AG·Filed 2018·Granted Jul 2, 2019·7 cites·22 claims
- 0686US7989441B2Organic compoundsNOVARTIS AG·Filed 2006·Granted Aug 2, 2011·8 cites·8 claims
- 0785US8957068B23-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDHCAFERRO THOMAS RAYMOND·Filed 2012·Granted Feb 17, 2015·13 cites·28 claims
- 0884US9416136B2Pyrrolopyrimidine compounds and their usesBESONG GILBERT·Filed 2014·Granted Aug 16, 2016·8 cites·23 claims
- 0982US2024043428A1Pyrrolopyrimidine compounds and their usesNOVARTIS AG·Filed 2022·Application pending·0 cites
- 1081US10975080B2Compounds and compositions for inhibiting the activity of SHP2NOVARTIS AG·Filed 2016·Granted Apr 13, 2021·2 cites·3 claims
- 1179US9181266B22-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitorsCHEUNG ATWOOD KIM·Filed 2012·Granted Nov 10, 2015·3 cites·13 claims
- 1279US2024199609A1Compounds and compositions for inhibiting the activity of shp2NOVARTIS AG·Filed 2023·Application pending·0 cites
- 1377US11958846B2Urea compounds and compositions as SMARCA2/BRM ATPase inhibitorsNOVARTIS AG·Filed 2019·Granted Apr 16, 2024·2 cites·11 claims
- 1477US2022073537A1N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2NOVARTIS AG·Filed 2021·Application pending·0 cites
- 1576US12358906B2Urea compounds and compositions as SMARCA2/BRM ATPase inhibitorsNOVARTIS AG·Filed 2024·Granted Jul 15, 2025·0 cites·13 claims
- 1675US11952386B2N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2NOVARTIS AG·Filed 2021·Granted Apr 9, 2024·0 cites·12 claims
- 1774US12209098B2N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2NOVARTIS AG·Filed 2021·Granted Jan 28, 2025·0 cites·26 claims
- 1873US2021253578A1Pyrrolopyrimidine compounds and their usesNOVARTIS AG·Filed 2020·Application pending·0 cites
- 1970US11905283B2Compounds and compositions for inhibiting the activity of SHP2NOVARTIS AG·Filed 2020·Granted Feb 20, 2024·0 cites·8 claims
- 2066US2021309663A1Compounds and compositions for inhbiting the activity of shp2NOVARTIS AG·Filed 2021·Application pending·0 cites
- 2165US2022089597A1Compounds and compositions for inhbiting the activity of shp2NOVARTIS AG·Filed 2021·Application pending·0 cites
- 2264US2018155351A1Pyrrolopyrimidine compounds and their usesNOVARTIS AG·Filed 2018·Application pending·0 cites
- 2359US2025145600A12-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesityNOVARTIS AG·Filed 2023·Application pending·0 cites
- 2456US2017183352A1Pyrrolopyrimidine compounds and their usesBESONG GILBERT·Filed 2016·Application pending·0 cites
- 2554US2024182456A12-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesityNOVARTIS AG·Filed 2022·Application pending·0 cites
- 2650US2011281845A1Organic compoundsCHEN ZHUOLIANG·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Troy Douglas Smith files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →